On this page
What each program costs in Washington
The monthly price is all-in: the drug plus a membership when we have verified one. Compounded drugs are not FDA-approved.
| # | Program | Cheapest product | Plan | All in | Membership fee | Trustpilot | Checked | Seller site |
|---|---|---|---|---|---|---|---|---|
| 1 | Compounded Semaglutide | sale price | $39/mo | not verified | too few reviews | Visit | ||
| 2 | Compounded Semaglutide | 12-month plan, $588 up front | $49/mo | none | 3.9 (11,798 reviews) | Visit | ||
| 3 | Compounded Semaglutide | month to month | $59/mo | none | too few reviews | Visit | ||
| 4 | Compounded Semaglutide | 12-month plan, $828 up front | $69/mo | none | 4.6 (4,268 reviews) | Visit | ||
| 5 | Compounded Semaglutide | month to month | $79/mo | none | too few reviews | Visit | ||
| 6 | Compounded Semaglutide | month to month | $99/mo | none | 4.6 (5,235 reviews) | Visit | ||
| 7 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.3 (880 reviews) | Visit | ||
| 8 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.2 (218 reviews) | Visit | ||
| 9 | Compounded Semaglutide | 12-month plan, $1,260 up front | $105/mo | none | too few reviews | Visit | ||
| 10 | Compounded Semaglutide | 12-month plan, $1,698 up front | $141/mo | none | too few reviews | Visit | ||
| 11 | Semaglutide | month to month | $149/mo | none | too few reviews | Visit | ||
| 12 | Compounded Semaglutide | 12-month plan, $1,788 up front | $149/mo | none | 4.2 (777 reviews) | Visit | ||
| 13 | Microdosing Tirzepatide | 12-month plan, $2,028 up front | $169/mo | none | 4.0 (162 reviews) | Visit | ||
| 14 | Compounded Semaglutide | 2-month plan, $350 up front | $175/mo | none | 4.6 (1,084 reviews) | Visit | ||
| 15 | Compounded Oral Semaglutide Capsules | 6-month plan, $1,194 up front | $199/mo | none | too few reviews | Visit | ||
| 16 | Foundayo (brand orforglipron) | medication monthly, membership yearly | $208/mo | $59/mo, billed yearly, included | 4.6 (4,607 reviews) | Visit | ||
| 17 | Sublingual Semaglutide | month to month | $249/mo | none | 4.5 (17,622 reviews) | Visit | ||
| 18 | Compounded Semaglutide | month to month | $299/mo | none | too few reviews | Visit |
Does the Washington Public Employees Benefits Board (PEBB) program cover GLP-1s for weight loss?
No Washington PEBB plan covers GLP-1 drugs for weight loss, as of the Health Care Authority's February 2026 newsletter.
What do Washington's big insurers publish on Wegovy and Zepbound?
Premera Blue Cross
Premera Blue Cross covers weight-management GLP-1s only when an employer group elects that benefit. In 2026 it added GLP-1 Access Select, an employer option that sets a BMI threshold of 35 for weight-loss GLP-1s.
Premera Blue Cross
Premera's February 19, 2026 employer update says weight-management GLP-1s are covered only when the employer elects the benefit.
“Weight management GLP-1s are reviewed under the weight-loss drug policy and are only covered when an employer group elects this benefit.”
https://employernews.premera.com/glp-1s-still-making-headlines/ · read Oct 29, 2026
Premera Blue Cross
Its June 2026 employer update describes GLP-1 Access Select, which sets a BMI threshold of 35.
“It sets a BMI threshold of 35 for weight loss GLP‑1s.”
https://employernews.premera.com/a-smarter-way-to-manage-glp-1-coverage-for-weight-management/ · read Oct 29, 2026
Does Washington Medicaid (Apple Health) cover GLP-1s for weight loss?
Not covered for weight loss
Washington Apple Health policy says Wegovy and Zepbound are not covered for weight loss, and state rule excludes any drug prescribed for weight loss. Read from state documents Nov 6, 2026.
What Washington Medicaid (Apple Health)'s documents say about each drug for weight loss. Read Nov 6, 2026. Washington State Health Care Authority.
WegovyNo
Not covered for weight loss. The policy has approval paths for heart risk with BMI 27 or higher and for a liver condition (MASH), with prior authorization. Age 20 and younger follow EPSDT rules.
“Semaglutide injection or tablet (Wegovy®) is not covered by Apple Health for weight loss in accordance with:”
Washington State Health Care Authority · Effective Feb 1, 2026 · read Nov 6, 2026
“(b) A drug prescribed: (i) For weight loss or gain;”
Washington Administrative Code, WAC 182-530-2100 (Health Care Authority rule) · Effective Nov 21, 2025 · read Nov 6, 2026
ZepboundNo
Not covered for weight loss. The policy has an approval path for moderate to severe sleep apnea in adults with BMI above 30, with prior authorization. Age 20 and younger follow EPSDT rules.
“Tirzepatide (Zepbound®) is not covered by Apple Health for weight loss in accordance with:”
Washington State Health Care Authority · Effective May 1, 2025 · read Nov 6, 2026
OzempicNo
State rule excludes any drug prescribed for weight loss. The GLP-1 policy requires a type 2 diabetes diagnosis or qualifying HbA1c, with prior authorization.
“(1) The medicaid agency does not cover:”
Washington Administrative Code, WAC 182-530-2100 (Health Care Authority rule) · Effective Nov 21, 2025 · read Nov 6, 2026
“(b) A drug prescribed: (i) For weight loss or gain;”
Washington Administrative Code, WAC 182-530-2100 (Health Care Authority rule) · Effective Nov 21, 2025 · read Nov 6, 2026
“Diagnosis of type 2 diabetes or an HbA1c ≥ 6.5 within the last 12 months;”
Washington State Health Care Authority · Effective Jul 1, 2026 · read Nov 6, 2026
MounjaroNo
State rule excludes any drug prescribed for weight loss. The GLP-1 policy requires a type 2 diabetes diagnosis or qualifying HbA1c, including its sleep apnea path, with prior authorization.
“(1) The medicaid agency does not cover:”
Washington Administrative Code, WAC 182-530-2100 (Health Care Authority rule) · Effective Nov 21, 2025 · read Nov 6, 2026
“(b) A drug prescribed: (i) For weight loss or gain;”
Washington Administrative Code, WAC 182-530-2100 (Health Care Authority rule) · Effective Nov 21, 2025 · read Nov 6, 2026
“Tirzepatide (Mounjaro) may be approved when all of the following documented criteria are met: 1. Diagnosis of Type 2 diabetes or an HbA1c ≥ 6.5 within the last 12 months;”
Washington State Health Care Authority · Effective Jul 1, 2026 · read Nov 6, 2026
This reports what the documents say. It is not medical or legal advice: your plan and your prescriber decide.
What changed, and when
- Nov 6, 2026 · This pageFirst read from Washington State Health Care Authority documents. KFF's January 2026 map listed this program as not covered; the documents we read agree.
Weight loss
Not covered, read Nov 2026
Type 2 diabetes
Required in every state
Heart risk, sleep apnea
Required (Wegovy, Zepbound)
Prior authorization
Typical when covered
Wegovy, Zepbound, Saxenda, 2025
3,462 prescriptions
Ozempic and Mounjaro, 2025
50,002 prescriptions
Neighbours covering weight loss
0 of 2
Federal law lets each state decide whether Medicaid pays for drugs used for weight loss, while drugs approved for diabetes must be covered. A state document may not settle every plan; if your Washington Medicaid coverage comes through a managed care plan, its formulary can differ, so ask the plan before you fill.
For comparison, a dated secondary source: KFF's January 2026 map listed Washington Medicaid as "not covered" for GLP-1s for obesity under fee-for-service.
The BALANCE model
CMS’s BALANCE model lets state Medicaid programs add GLP-1s for weight management at a negotiated price. States could join on a rolling basis from May 1, 2026 through January 1, 2027, and the state application deadline was July 31, 2026. We could not find a published list of the states that joined, so this page does not say whether Washington Medicaid did. Ask your plan. Either way your cost stays at Medicaid’s nominal copay, which BALANCE does not change.
The national picture, coupons and patient assistance: does Medicaid cover GLP-1s.
How many GLP-1s does Washington Medicaid pay for?
111,160 GLP-1 prescriptions in 2025, 23rd of the 50 states and DC, with $79.7 million reimbursed before rebates. Counting the share other payers covered, $82.6 million.
Prescriptions, 2025
111,160
23rd of 51
Medicaid paid
$79.7M
27th of 51, before rebates
Per prescription
$717
$1,051 nationally
Weight-loss brands
3.1%
28th highest share of 51
CMS State Drug Utilization Data 2025, updated Jul 13, 2026, fee-for-service and managed care, before rebates. Washington is highlighted. CMS publishes this comparison as one year, not a trend.
Wegovy, Zepbound and Saxenda, the brands approved for weight management, were 3.1% of Washington Medicaid's GLP-1 prescriptions in 2025 (3,462). Across the 13 states KFF lists as covering GLP-1s for obesity, the median share was 52%; across the other 38, 2.3%. Where weight loss is not covered, those brands are mostly filled for the uses Medicaid must cover, such as heart risk and sleep apnea. Liraglutide (generic) was Washington Medicaid's most filled GLP-1.
| Brand | Prescriptions | Share | Medicaid paid | Per Rx |
|---|---|---|---|---|
| Liraglutide (generic) | 47,673 | 43% | $18.6 million | $391 |
| Ozempic | 28,320 | 25% | $26.6 million | $939 |
| Mounjaro | 21,682 | 20% | $21.7 million | $999 |
| Trulicity | 3,779 | 3.4% | $3.5 million | $934 |
| Bydureon | 3,431 | 3.1% | $2.8 million | $816 |
| Zepboundapproved for weight management | 2,247 | 2.0% | $2.4 million | $1,060 |
| Rybelsus | 1,629 | 1.5% | $1.7 million | $1,042 |
| Wegovyapproved for weight management | 1,215 | 1.1% | $1.6 million | $1,307 |
| Victoza | 879 | 0.8% | $565,090 | $643 |
| Byetta | 228 | 0.2% | $192,742 | $845 |
| Exenatide (generic) | 77 | 0.1% | $55,225 | $717 |
Source: CMS State Drug Utilization Data 2025, updated Jul 13, 2026, all four quarters, fee-for-service and managed care. Before rebates. CMS suppresses rows under 11 prescriptions, so small brands are undercounted slightly. Every state ranked: prescriptions and spending.
On Medicare in Washington?
Medicare’s temporary GLP-1 Bridge works the same in every state: a $50 copay for a one-month supply of Wegovy, Foundayo or the Zepbound KwikPen, for people with Part D who meet its weight and health rules.
medicare.gov
“You’ll pay a $50 copayment to the pharmacy for a one-month supply (either 28 or 30 days, depending on drug).”
https://www.medicare.gov/coverage/weight-loss-drugs · read Nov 14, 2026
Washington and the states around it
Medicaid’s weight-loss answer (the state’s own documents where we have read them, otherwise KFF, January 2026) and the partner programs that ship there, priced the same way as above.
None of the 2 states next to Washington covers GLP-1s for weight loss through Medicaid. None has a lower cash floor than Washington's $39.





















